\-\ Texto\\:\\ \ \(0\)\
\-\ standard\\ treatment\\:\\ abvd\\ w\\/xrt\ \(0\)\
\-\ adriamycin\\ \\[doxorubicin\\]\\,\\ bleomycin\\,\\ vinblastine\\,\\ dacarbazine\ \(0\)\
\-\ prognosis\\ is\\ good\\,\\ especially\\ for\\ young\\ pts\\ with\\ early\\-stage\\ disease\\ 5\\ year\\ survival\\ rate\\ of\\ 90\\%\ \(0\)\
\-\ \\‚\\Ä\\¢\\ anterior\\ \\(superior\\)\\ mediastinal\\ mass\\,\\ surrounding\\ the\\ great\\ vessels\\ and\\ aortic\\ arch\\.\ \(0\)\
\-\ nodular\\ sclerosing\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\ \(0\)\
\-\ mediastinal\\ mass\\:\ \(2\)\
\-\ \\‚\\Ä\\¢\\ thymoma\\ \ \(0\)\
\-\ most\\ common\\ 1\\¬\\∞\\ anterior\\ mediastinal\\ mass\\ \\(20\\%\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ lymphoma\ \(6\)\
\-\ \\‚\\Ä\\¢\\ germ\\ cell\\ tumors\ \(1\)\
\-\ \\‚\\Ä\\¢\\ mediastinal\\ cysts\ \(0\)\
\-\ \\‚\\Ä\\¢\\ pericardial\\,\\ bronchogenic\\,\\ enteric\\,\\ thymic\ \(0\)\
\-\ \\‚\\Ä\\¢\\ aneurysm\\ of\\ ascending\\ aorta\ \(0\)\
\-\ \\‚\\Ä\\¢\\ thyroid\\/parathyroid\\ tissue\ \(0\)\
\-\ a\\ previously\\ healthy\\ 23\\ y\\/o\\ woman\\ presents\\ with\\ a\\ 4\\-month\\ history\\ of\\ itchy\\ skin\\,\\ night\\ sweats\\,\\ and\\ a\\ 20\\-lb\\ unintentional\\ weight\\ loss\\.\ \(0\)\
\-\ \\‚\\Ä\\¢\\ signs\\ \\&\\ symptoms\ \(0\)\
\-\ often\\ asymptomatic\\ \ \(1\)\
\-\ most\\ common\\ \\=\\ painless\\ lymphadenopathy\ \(0\)\
\-\ 1\\/3\\ of\\ pts\\ present\\ w\\/systemic\\ symptoms\ \(1\)\
\-\ fatigue\\,\\ generalized\\ pruritis\\,\\ \\‚\\Ä\\úb\\‚\\Ä\\ù\\ symptoms\\ \\[low\\-grade\\ fever\\,\\ night\\ sweats\\,\\ weight\\ loss\\]\ \(0\)\
\-\ mediastinal\\ masses\\ may\\ also\\ produce\\ mass\\ effects\ \(0\)\
\-\ \\‚\\Ä\\¢\\ subtypes\ \(0\)\
\-\ nodular\\ sclerosing\ \(5\)\
\-\ mixed\\ cellularity\\ \ \(1\)\
\-\ lymphocyte\\-depleted\ \(0\)\
\-\ lymphocyte\\-rich\ \(0\)\
\-\ nodular\\ lymphocyte\\-predominant\ \(0\)\
\-\ \\‚\\Ä\\¢\\ nodular\\ sclerosing\\ subtype\ \(0\)\
\-\ most\\ common\\ subtype\\ in\\ the\\ us\ \(0\)\
\-\ affects\\ females\\ \\>\\ males\ \(0\)\
\-\ median\\ age\\ of\\ onset\\ \\=\\ mid\\-20\\‚\\Ä\\ôs\ \(0\)\
\-\ \\‚\\Ä\\¢\\ bimodal\\ peak\\ distribution\\ of\\ onset\\ \ \(0\)\
\-\ young\\ adults\\ \\(15\\-35\\)\\ and\\ late\\ adulthood\\ \\(\\>55\\)\ \(0\)\
\-\ associated\\ with\\ ebv\\ and\\ hiv\ \(0\)\
\-\ http\\:\\/\\/www\\.uptodate\\.com\\/contents\\/anterior\\-mediastinal\\-mass\\-lesions\ \(1\)\
\-\ http\\:\\/\\/emedicine\\.medscape\\.com\\/article\\/201886\\-overview\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\:\\ 0\\.08357409875178069\ \(0\)\
\-\ mediastinal\\:\\ 0\\.08062516929168317\ \(0\)\
\-\ sclerosing\\:\\ 0\\.06739091077697247\ \(0\)\
\-\ nodular\\:\\ 0\\.06372284101532287\ \(0\)\
\-\ pts\\:\\ 0\\.052667970365069636\ \(0\)\
\-\ subtype\\:\\ 0\\.05129774209993844\ \(0\)\
\-\ sweats\\:\\ 0\\.04323799738120063\ \(0\)\
\-\ \\=\\:\\ 0\\.039864756299379266\ \(0\)\
\-\ \\]\\:\\ 0\\.03974856001878057\ \(0\)\
\-\ \\[\\:\\ 0\\.039633863086905835\ \(0\)\
\-\ abvd\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ w\\/xrt\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ dacarbazine\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ 1\\¬\\∞\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ thyroid\\/parathyroid\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ 4\\-month\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ itchy\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ 20\\-lb\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ w\\/systemic\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ lymphocyte\\-depleted\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ lymphocyte\\-rich\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ lymphocyte\\-predominant\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ mid\\-20\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ \\/\\/www\\.uptodate\\.com\\/contents\\/anterior\\-mediastinal\\-mass\\-lesions\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ \\/\\/emedicine\\.medscape\\.com\\/article\\/201886\\-overview\\:\\ 0\\.039180081884295545\ \(0\)\
\-\ night\\:\\ 0\\.03690737182092828\ \(0\)\
\-\ early\\-stage\\:\\ 0\\.03609942774847357\ \(0\)\
\-\ 15\\-35\\:\\ 0\\.03609942774847357\ \(0\)\
\-\ young\\:\\ 0\\.03308238420586432\ \(0\)\
\-\ adriamycin\\:\\ 0\\.032027024495699545\ \(0\)\
\-\ bleomycin\\:\\ 0\\.032027024495699545\ \(0\)\
\-\ vinblastine\\:\\ 0\\.032027024495699545\ \(0\)\
\-\ bimodal\\:\\ 0\\.03121670646550419\ \(0\)\
\-\ common\\:\\ 0\\.02981689615941863\ \(0\)\
\-\ pruritis\\:\\ 0\\.028946370359877568\ \(0\)\
\-\ cellularity\\:\\ 0\\.028946370359877568\ \(0\)\
\-\ http\\:\\ 0\\.02876256531538023\ \(0\)\
\-\ unintentional\\:\\ 0\\.028522769560747233\ \(0\)\
\-\ symptoms\\:\\ 0\\.028395433025308524\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.02745093819711662\ \(0\)\
\-\ ebv\\:\\ 0\\.02745093819711662\ \(0\)\
\-\ weight\\:\\ 0\\.02722618475680769\ \(0\)\
\-\ most\\:\\ 0\\.02630446855637435\ \(0\)\
\-\ subtypes\\:\\ 0\\.02564887104996922\ \(0\)\
\-\ adulthood\\:\\ 0\\.025442115424925256\ \(0\)\
\-\ \\>\\:\\ 0\\.025237044574831682\ \(0\)\
\-\ 1\\/3\\:\\ 0\\.02469965282642229\ \(0\)\
\-\ thymic\\:\\ 0\\.02453191803538742\ \(0\)\
\-\ onset\\:\\ 0\\.02397707756377911\ \(0\)\
\-\ thymoma\\:\\ 0\\.02377681120518565\ \(0\)\
\-\ hodgkin\\:\\ 0\\.023640048277777857\ \(0\)\
\-\ low\\-grade\\:\\ 0\\.023253331046712837\ \(0\)\
\-\ enteric\\:\\ 0\\.022785062088233606\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.022702459907959608\ \(0\)\
\-\ effects\\:\\ 0\\.02216389789989957\ \(0\)\
\-\ loss\\:\\ 0\\.022048570421941686\ \(0\)\
\-\ median\\:\\ 0\\.021974744058038256\ \(0\)\
\-\ males\\:\\ 0\\.02188310278158165\ \(0\)\
\-\ s\\:\\ 0\\.021784601485462997\ \(0\)\
\-\ lymphoma\\:\\ 0\\.021708432305684318\ \(0\)\
\-\ affects\\:\\ 0\\.021618998690600313\ \(0\)\
\-\ peak\\:\\ 0\\.021618998690600313\ \(0\)\
\-\ females\\:\\ 0\\.02113366850408924\ \(0\)\
\-\ mass\\:\\ 0\\.021128195679067815\ \(0\)\
\-\ produce\\:\\ 0\\.02105769324471457\ \(0\)\
\-\ hiv\\:\\ 0\\.02105769324471457\ \(0\)\
\-\ great\\:\\ 0\\.02069615706936367\ \(0\)\
\-\ pericardial\\:\\ 0\\.02042671430573507\ \(0\)\
\-\ survival\\:\\ 0\\.02036183075275217\ \(0\)\
\-\ ascending\\:\\ 0\\.02036183075275217\ \(0\)\
\-\ fatigue\\:\\ 0\\.02029788080852062\ \(0\)\
\-\ \\:\\:\\ 0\\.02009377450650071\ \(0\)\
\-\ bronchogenic\\:\\ 0\\.020050903692277015\ \(0\)\
\-\ generalized\\:\\ 0\\.019874280009390285\ \(0\)\
\-\ late\\:\\ 0\\.019760313651108787\ \(0\)\
\-\ germ\\:\\ 0\\.019649196752418042\ \(0\)\
\-\ anterior\\:\\ 0\\.019562602877890998\ \(0\)\
\-\ standard\\:\\ 0\\.01943496518878303\ \(0\)\
\-\ adults\\:\\ 0\\.019382982789835513\ \(0\)\
\-\ painless\\:\\ 0\\.01908324376407759\ \(0\)\
\-\ 55\\:\\ 0\\.018411953731131518\ \(0\)\
\-\ 23\\:\\ 0\\.018053014368267263\ \(0\)\
\-\ prognosis\\:\\ 0\\.01801486439630552\ \(0\)\
\-\ 90\\:\\ 0\\.017902340805264233\ \(0\)\
\-\ b\\:\\ 0\\.017902340805264233\ \(0\)\
\-\ \\%\\:\\ 0\\.017718409185297844\ \(0\)\
\-\ healthy\\:\\ 0\\.01712299463869596\ \(0\)\
\-\ arch\\:\\ 0\\.01709202277506888\ \(0\)\
\-\ distribution\\:\\ 0\\.01709202277506888\ \(0\)\
\-\ \\,\\:\\ 0\\.01684418185440899\ \(0\)\
\-\ mixed\\:\\ 0\\.016679659515286806\ \(0\)\
\-\ aorta\\:\\ 0\\.016302328654013536\ \(0\)\
\-\ good\\:\\ 0\\.016250947221119864\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.016149932771886283\ \(0\)\
\-\ previously\\:\\ 0\\.015954541112236875\ \(0\)\
\-\ us\\:\\ 0\\.015930710253830718\ \(0\)\
\-\ especially\\:\\ 0\\.015632004699637606\ \(0\)\
\-\ aortic\\:\\ 0\\.015373031774642158\ \(0\)\
\-\ vessels\\:\\ 0\\.01528995562792148\ \(0\)\
\-\ aneurysm\\:\\ 0\\.015010840511303568\ \(0\)\
\-\ cysts\\:\\ 0\\.014877592368139408\ \(0\)\
\-\ rate\\:\\ 0\\.01480320662433708\ \(0\)\
\-\ skin\\:\\ 0\\.014587239712173235\ \(0\)\
\-\ tumors\\:\\ 0\\.014265406034091115\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.014184448523462932\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.01410493934679282\ \(0\)\
\-\ 20\\:\\ 0\\.01365562327180896\ \(0\)\
\-\ signs\\:\\ 0\\.013366115262160241\ \(0\)\
\-\ \\&\\:\\ 0\\.013339501742850807\ \(0\)\
\-\ fever\\:\\ 0\\.012850056118008739\ \(0\)\
\-\ \\(\\:\\ 0\\.012841986244335298\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.012838188435538165\ \(0\)\
\-\ masses\\:\\ 0\\.012838188435538165\ \(0\)\
\-\ \\)\\:\\ 0\\.012685114526458758\ \(0\)\
\-\ surrounding\\:\\ 0\\.01248517895273229\ \(0\)\
\-\ superior\\:\\ 0\\.012127749764685294\ \(0\)\
\-\ often\\:\\ 0\\.012117660215642898\ \(0\)\
\-\ age\\:\\ 0\\.011559601446863584\ \(0\)\
\-\ 5\\:\\ 0\\.011111824099751836\ \(0\)\
\-\ y\\/o\\:\\ 0\\.010518351243642848\ \(0\)\
\-\ cell\\:\\ 0\\.010258847607028828\ \(0\)\
\-\ tissue\\:\\ 0\\.009001871948678195\ \(0\)\
\-\ associated\\:\\ 0\\.008962055830700897\ \(0\)\
\-\ woman\\:\\ 0\\.008772901988839583\ \(0\)\
\-\ present\\:\\ 0\\.008577816684140803\ \(0\)\
\-\ may\\:\\ 0\\.008330348306213884\ \(0\)\
\-\ \\-\\:\\ 0\\.008141015372037172\ \(0\)\
\-\ presents\\:\\ 0\\.007758419091146337\ \(0\)\
\-\ treatment\\:\\ 0\\.0076871864871150535\ \(0\)\
\-\ also\\:\\ 0\\.007487198194089562\ \(0\)\
\-\ disease\\:\\ 0\\.006207722405403129\ \(0\)\
\-\ a\\:\\ 0\\.005287997357581351\ \(0\)\
\-\ history\\:\\ 0\\.005245397945364815\ \(0\)\
\-\ year\\:\\ 0\\.004249356752324065\ \(0\)\
\-\ for\\:\\ 0\\.0032404806606342895\ \(0\)\
\-\ and\\:\\ 0\\.003200160101906106\ \(0\)\
\-\ of\\:\\ 0\\.0031067680212796918\ \(0\)\
\-\ is\\:\\ 0\\.002499070126154336\ \(0\)\
\-\ in\\:\\ 0\\.001872876578401133\ \(0\)\
\-\ with\\:\\ 0\\.00156005568119853\ \(0\)\
\-\ the\\:\\ 0\\.001228882530698896\ \(0\)\
\-\ \\.\\:\\ 0\\.0003155514319764113\ \(0\)\
